Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory myeloma~* M-protein in serum and/or urine by IMWG criteria.~* Bone marrow plasma cells or plasmacytoma~* Related organ or tissue impairment (CRAB)~* Subjects without detectable M protein are eligible if they have an abnormal serum free light chain ratio (FLC) or if they have at least 10% plasma cells in the bone marrow~Exclusion Criteria:~* Ongoing infection~* Cardiac disease~* Uncontrolled hypertension~* Active liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BIW-8962, monoclonal antibody (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).